Literature DB >> 23469951

Therapeutic effects of renal denervation on renal failure.

Yutang Wang1, Sai-Wang Seto, Jonathan Golledge.   

Abstract

Sympathetic nerve activity (SNA) is increased in both patients and experimental animals with renal failure. The kidney is a richly innervated organ and has both efferent and afferent nerves. Renal denervation shows protective effects against renal failure in both animals and humans. The underlying mechanisms include a decrease in blood pressure, a decrease in renal efferent SNA, a decrease in central SNA and sympathetic outflow, and downregulation of the reninangiotensin system. It has been demonstrated that re-innervation occurs within weeks after renal denervation in animals but that no functional re-innervation occurs in humans for over two years after denervation. Renal denervation might not be renal protective in some situations including bile duct ligation-induced renal failure and ischemia/reperfusion-induced acute kidney injury. Catheter-based renal denervation has been applied to patients with both early and end stage renal failure and the published results so far suggest that this procedure is safe and effective at decreasing blood pressure. The effectiveness of renal denervation in improving renal function in patients with renal failure needs to be further investigated.

Entities:  

Mesh:

Year:  2013        PMID: 23469951     DOI: 10.2174/1567202611310020010

Source DB:  PubMed          Journal:  Curr Neurovasc Res        ISSN: 1567-2026            Impact factor:   1.990


  2 in total

1.  Catheter-based Renal Sympathetic Denervation - Long-term Symplicity™ Renal Denervation Clinical Evidence, New Data and Future Perspectives.

Authors:  Katrina Mountfort; Felix Mahfoud; Roland Schmieder; Justin Davies; David E Kandzari; Joachim Weil; Robert Whitbourn
Journal:  Interv Cardiol       Date:  2013-08

2.  Protective effect of epigallocatechin gallate, a major constituent of green tea, against renal ischemia-reperfusion injury in rats.

Authors:  Jun Lv; Min Feng; LiLi Zhang; Xia Wan; Yu Chun Zeng; Pei Fen Liang; An Ping Xu
Journal:  Int Urol Nephrol       Date:  2015-06-28       Impact factor: 2.370

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.